2024-02-012025-01-312025-01-31false14583026BH PHARMACY LTD2025-07-09falseiso4217:GBPxbrli:pure145830262024-01-31145830262025-01-31145830262024-02-012025-01-31145830262023-01-09145830262024-01-31145830262023-01-102024-01-3114583026bus:SmallEntities2024-02-012025-01-3114583026bus:AuditExempt-NoAccountantsReport2024-02-012025-01-3114583026bus:AbridgedAccounts2024-02-012025-01-3114583026bus:PrivateLimitedCompanyLtd2024-02-012025-01-3114583026core:WithinOneYear2025-01-3114583026core:AfterOneYear2025-01-3114583026core:WithinOneYear2024-01-3114583026core:AfterOneYear2024-01-3114583026core:ShareCapital2025-01-3114583026core:SharePremium2025-01-3114583026core:RevaluationReserve2025-01-3114583026core:OtherReservesSubtotal2025-01-3114583026core:RetainedEarningsAccumulatedLosses2025-01-3114583026core:ShareCapital2024-01-3114583026core:SharePremium2024-01-3114583026core:RevaluationReserve2024-01-3114583026core:OtherReservesSubtotal2024-01-3114583026core:RetainedEarningsAccumulatedLosses2024-01-3114583026core:LandBuildings2025-01-3114583026core:PlantMachinery2025-01-3114583026core:Vehicles2025-01-3114583026core:FurnitureFittings2025-01-3114583026core:OfficeEquipment2025-01-3114583026core:NetGoodwill2025-01-3114583026core:IntangibleAssetsOtherThanGoodwill2025-01-3114583026core:ListedExchangeTraded2025-01-3114583026core:UnlistedNon-exchangeTraded2025-01-3114583026core:LandBuildings2024-01-3114583026core:PlantMachinery2024-01-3114583026core:Vehicles2024-01-3114583026core:FurnitureFittings2024-01-3114583026core:OfficeEquipment2024-01-3114583026core:NetGoodwill2024-01-3114583026core:IntangibleAssetsOtherThanGoodwill2024-01-3114583026core:ListedExchangeTraded2024-01-3114583026core:UnlistedNon-exchangeTraded2024-01-3114583026core:LandBuildings2024-02-012025-01-3114583026core:PlantMachinery2024-02-012025-01-3114583026core:Vehicles2024-02-012025-01-3114583026core:FurnitureFittings2024-02-012025-01-3114583026core:OfficeEquipment2024-02-012025-01-3114583026core:NetGoodwill2024-02-012025-01-3114583026core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3114583026core:ListedExchangeTraded2024-02-012025-01-3114583026core:UnlistedNon-exchangeTraded2024-02-012025-01-3114583026core:MoreThanFiveYears2024-02-012025-01-3114583026core:Non-currentFinancialInstruments2025-01-3114583026core:Non-currentFinancialInstruments2024-01-3114583026dpl:CostSales2024-02-012025-01-3114583026dpl:DistributionCosts2024-02-012025-01-3114583026core:LandBuildings2024-02-012025-01-3114583026core:PlantMachinery2024-02-012025-01-3114583026core:Vehicles2024-02-012025-01-3114583026core:FurnitureFittings2024-02-012025-01-3114583026core:OfficeEquipment2024-02-012025-01-3114583026dpl:AdministrativeExpenses2024-02-012025-01-3114583026core:NetGoodwill2024-02-012025-01-3114583026core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3114583026dpl:GroupUndertakings2024-02-012025-01-3114583026dpl:ParticipatingInterests2024-02-012025-01-3114583026dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-012025-01-3114583026core:ListedExchangeTraded2024-02-012025-01-3114583026dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-012025-01-3114583026core:UnlistedNon-exchangeTraded2024-02-012025-01-3114583026dpl:CostSales2023-01-102024-01-3114583026dpl:DistributionCosts2023-01-102024-01-3114583026core:LandBuildings2023-01-102024-01-3114583026core:PlantMachinery2023-01-102024-01-3114583026core:Vehicles2023-01-102024-01-3114583026core:FurnitureFittings2023-01-102024-01-3114583026core:OfficeEquipment2023-01-102024-01-3114583026dpl:AdministrativeExpenses2023-01-102024-01-3114583026core:NetGoodwill2023-01-102024-01-3114583026core:IntangibleAssetsOtherThanGoodwill2023-01-102024-01-3114583026dpl:GroupUndertakings2023-01-102024-01-3114583026dpl:ParticipatingInterests2023-01-102024-01-3114583026dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-102024-01-3114583026core:ListedExchangeTraded2023-01-102024-01-3114583026dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-102024-01-3114583026core:UnlistedNon-exchangeTraded2023-01-102024-01-3114583026core:NetGoodwill2025-01-3114583026core:IntangibleAssetsOtherThanGoodwill2025-01-3114583026core:LandBuildings2025-01-3114583026core:PlantMachinery2025-01-3114583026core:Vehicles2025-01-3114583026core:FurnitureFittings2025-01-3114583026core:OfficeEquipment2025-01-3114583026core:AfterOneYear2025-01-3114583026core:WithinOneYear2025-01-3114583026core:ListedExchangeTraded2025-01-3114583026core:UnlistedNon-exchangeTraded2025-01-3114583026core:ShareCapital2025-01-3114583026core:SharePremium2025-01-3114583026core:RevaluationReserve2025-01-3114583026core:OtherReservesSubtotal2025-01-3114583026core:RetainedEarningsAccumulatedLosses2025-01-3114583026core:NetGoodwill2024-01-3114583026core:IntangibleAssetsOtherThanGoodwill2024-01-3114583026core:LandBuildings2024-01-3114583026core:PlantMachinery2024-01-3114583026core:Vehicles2024-01-3114583026core:FurnitureFittings2024-01-3114583026core:OfficeEquipment2024-01-3114583026core:AfterOneYear2024-01-3114583026core:WithinOneYear2024-01-3114583026core:ListedExchangeTraded2024-01-3114583026core:UnlistedNon-exchangeTraded2024-01-3114583026core:ShareCapital2024-01-3114583026core:SharePremium2024-01-3114583026core:RevaluationReserve2024-01-3114583026core:OtherReservesSubtotal2024-01-3114583026core:RetainedEarningsAccumulatedLosses2024-01-3114583026core:NetGoodwill2023-01-0914583026core:IntangibleAssetsOtherThanGoodwill2023-01-0914583026core:LandBuildings2023-01-0914583026core:PlantMachinery2023-01-0914583026core:Vehicles2023-01-0914583026core:FurnitureFittings2023-01-0914583026core:OfficeEquipment2023-01-0914583026core:AfterOneYear2023-01-0914583026core:WithinOneYear2023-01-0914583026core:ListedExchangeTraded2023-01-0914583026core:UnlistedNon-exchangeTraded2023-01-0914583026core:ShareCapital2023-01-0914583026core:SharePremium2023-01-0914583026core:RevaluationReserve2023-01-0914583026core:OtherReservesSubtotal2023-01-0914583026core:RetainedEarningsAccumulatedLosses2023-01-0914583026core:AfterOneYear2024-02-012025-01-3114583026core:WithinOneYear2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:CostValuation2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3114583026core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3114583026core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3114583026core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3114583026core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3114583026core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3114583026bus:Director12024-02-012025-01-31

BH PHARMACY LTD

Registered Number
14583026
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2025

BH PHARMACY LTD
Company Information
for the year from 1 February 2024 to 31 January 2025

Director

HOFFMANN, Bartosz

Registered Address

226 Sandy Lane
Droylsden
Manchester
M43 7JX

Registered Number

14583026 (England and Wales)
BH PHARMACY LTD
Balance Sheet as at
31 January 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3293,180327,672
Tangible assets45,2533,635
298,433331,307
Current assets
Stocks20,54337,543
Debtors5119,587127,261
Cash at bank and on hand230,25753,384
370,387218,188
Creditors amounts falling due within one year6(184,438)(125,264)
Net current assets (liabilities)185,94992,924
Total assets less current liabilities484,382424,231
Creditors amounts falling due after one year7(426,508)(416,611)
Provisions for liabilities(1,313)(691)
Net assets56,5616,929
Capital and reserves
Called up share capital100100
Profit and loss account56,4616,829
Shareholders' funds56,5616,929
The financial statements were approved and authorised for issue by the Director on 9 July 2025, and are signed on its behalf by:
HOFFMANN, Bartosz
Director
Registered Company No. 14583026
BH PHARMACY LTD
Notes to the Financial Statements
for the year ended 31 January 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Defined contribution pension plan
The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Borrowing costs
Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Goodwill
Goodwill arising on an acquisition of a business is carried at cost less accumulated impairment losses, if any. Goodwill is amortised over its expected useful life which is estimated to be ten years. Goodwill is assessed for impairment when there are indicators of impairment and any impairment is charged to the income statement. No reversals of impairment are recognised.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Plant and machinery20
Fixtures and fittings20
Office Equipment20
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Financial assets which are measured at cost or amortised cost are reviewed for objective evidence of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. All equity instruments, regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

20252024
Average number of employees during the year55
3.Intangible assets

Total

£
Cost or valuation
At 01 February 24327,672
At 31 January 25293,180
Amortisation and impairment
Charge for year34,492
Net book value
At 31 January 25293,180
At 31 January 24327,672
4.Tangible fixed assets

Total

£
Cost or valuation
At 01 February 243,635
Additions2,931
At 31 January 255,253
Depreciation and impairment
Charge for year1,313
Net book value
At 31 January 255,253
At 31 January 243,635
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables96,08175,099
Other debtors13,65842,929
Prepayments and accrued income9,8489,233
Total119,587127,261
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables129,713100,535
Bank borrowings and overdrafts12,88619,497
Taxation and social security40,2065,232
Accrued liabilities and deferred income1,633-
Total184,438125,264
The prior year balance included a duplicated supplier invoice of £339 which has been corrected in the current year. Comparative figures have not been restated.
7.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts263,746266,849
Other creditors162,762149,762
Total426,508416,611
8.Secured creditors
The company continues to repay a mortgage used to finance the purchase of business goodwill. The loan is secured against the goodwill and other business assets, with a legal charge registered at Companies House. It is repayable in monthly instalments over a 15-year term, with interest fixed at 7.38% per annum. At 31 January 2025, the outstanding balance was £276,631.56, of which £12,885.65 is due within one year and £263,745.91 is due after more than one year.
9.Related party transactions
At 31 January 2025, the company owed £162,762.58 (2024: £149,762.10) to a director who is also a shareholder. The loan was provided to assist with the acquisition of the business. It is unsecured, interest-free, and repayable after more than one year.